# Continuous Steroid Monitoring in Interstitial Fluid With Wearable and Nanoparticle-enhanced Biosensors for Improved Management of Adrenal Disorders

Study · id `cardio:ct-nct06980753` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06980753](<https://clinicaltrials.gov/study/NCT06980753>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06980753

Browse, organ or system: Blood vessels; Kidneys  
Browse, condition area: High blood pressure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 246 participants.

## Technical summary

Registry record NCT06980753. Allocation not applicable; no masking; primary purpose diagnostic. Start 2025-06-01 (anticipated); primary completion 2025-11-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Not applicable
- Enrolled: 246 participants (planned count; ClinicalTrials.gov record NCT06980753, source copy `cardio:ctgov-nct06980753-2025-05-20`, retrieved 2026-10-31)
- Planned start: 2025-06-01 (anticipated) (ClinicalTrials.gov record NCT06980753, source copy `cardio:ctgov-nct06980753-2025-05-20`, retrieved 2026-10-31)
- Primary completion: 2025-11-01 (anticipated) (ClinicalTrials.gov record NCT06980753, source copy `cardio:ctgov-nct06980753-2025-05-20`, retrieved 2026-10-31)
- Completion: 2025-12-01 (anticipated) (ClinicalTrials.gov record NCT06980753, source copy `cardio:ctgov-nct06980753-2025-05-20`, retrieved 2026-10-31)
- Countries: Brazil (ClinicalTrials.gov record NCT06980753, source copy `cardio:ctgov-nct06980753-2025-05-20`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06980753-2025-05-20`, retrieved 2026-10-31)

## The registry's words

- Brief title: Continuous Steroid Monitoring in Interstitial Fluid With Wearable and Nanoparticle-enhanced Biosensors for Improved Management of Adrenal Disorders
- Condition: Cushing Syndrome
- Condition: Primary Aldosteronism
- Condition: Adrenal Insufficiency
- Intervention (Device): Participants will use the biossensor for 48 h
- Lead sponsor: University of Sao Paulo General Hospital
- Lead sponsor class: OTHER
- Collaborator: Swiss Federal Institute of Technology in Zurich (ETH Zurich)
- Collaborator class: UNKNOWN
- Collaborator: Fundação de Amparo à Pesquisa do Estado de São Paulo
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Primary aldosteronism (`cardio:primary-aldosteronism`)
- Registry lists this organization as the lead sponsor: University of Sao Paulo General Hospital (`cardio:org-university-of-sao-paulo-general-hospital`)
- Registry lists this organization as a collaborator: Fundação de Amparo à Pesquisa do Estado de São Paulo (`cardio:org-fundacao-de-amparo-a-pesquisa-do-estado-de-sao-paulo`)

## Provenance

Content hash: b0eb563eccc1c10b39790b622d915abbbf077ad3d7de319618cc332cd6594df3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
